Company intelligence / Profile preview

NovaSight

Mishmar HaYarden, North District, Israelnova-sight.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

NovaSight has developed FDA-cleared digital therapies for amblyopia that replace traditional patching with a home-based, child-friendly system using 3D glasses and streamed content. Clinical studies have shown sustained improvements in visual acuity and compliance compared to standard care. The company’s EyeSwift device enables rapid, objective screening of multiple pediatric vision disorders[3][6][7].

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapy
Industry: Digital Health Medical Devices

Drug pipeline

4 assets

CureSight

Commercial

Indications: Amblyopia

3 more assets in the full pipeline.

Request access →

Partnerships

Rimonci Capital (strategic investor from pharma/device sector)

Beyond the preview

Go deeper on NovaSight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaSight.

Explore the full profile